Physician profile
Phillip D Compton
NPI 1578591186
$10,022.83
in general payments reported to CMS, 2019-2025
45 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $759 · 2021: $1,636 · 2022: $1,682 · 2023: $1,523 · 2024: $1,508 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,649 · Education: $95.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.51 |
| Education | $95.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,809.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $827.43 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $715.01 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $685.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $613.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $602.18 | 2019-2023 | Myrbetriq |
| Amgen INC. | $561.09 | 2019-2025 | Evenity, Prolia, Repatha |
| Sumitomo Pharma America, INC. | $457.72 | 2023-2025 | Gemtesa |
| Pfizer INC. | $424.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.11 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $306.68 | 2021-2025 | Vraylar, Ubrelvy |
| Lundbeck LLC | $254.69 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $199.95 | 2022-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $195.45 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179.53 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.